HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I/II clinical safety studies of terameprocol vaginal ointment.

AbstractOBJECTIVES:
Terameprocol (M4N, EM-1421) is a novel transcription inhibitor that selectively interferes with HPV viral genes E6/E7 with Sp1-dependent promoters, and induces apoptosis by inactivation of the CDC2/cyclin B complex (maturation promoting factor) and production and phosphorylation of survivin. This trial was designed to define the maximum tolerated dose (MTD), dose-limiting toxicity and determine the pharmacokinetic profiles of intravaginal terameprocol in women with HPV-linked cervical squamous intraepithelial neoplasia.
METHODS:
An open label, dose escalation Phase I/II clinical trial enrolled women with biopsy confirmed CIN 1, 2 or 3. Terameprocol (45 or 90 mg) was physician-administered directly to the cervix uteri in 3 once weekly applications. The pharmacokinetics after administration were examined on Day 1 of dosing. Patients underwent colposcopic examinations, HPV testing, biomarker assessments, cytology and cervical punch biopsy.
RESULTS:
Recruitment ended March 30, 2006 and 7 patients were enrolled. Median age was 24 years. There were no serious adverse events (SAEs) and possible treatment-related Adverse Events (AEs) reported were mild and self-limiting. There was no detectable absorption of terameprocol from the vaginal ointment application.
CONCLUSIONS:
Terameprocol in 1% and 2% vaginal ointment use in Phase I/II trials with women with HPV-linked cervical intraepithelial neoplasia has an excellent safety profile, no SAEs reported and mild, self-limiting treatment-related AEs. There was no detectable absorption of terameprocol. These data support the continued evaluation of terameprocol in in vitro and animal efficacy models followed by definitive human Phase II clinical trials in CIN.
AuthorsNiharika Khanna, Richard Dalby, Ming Tan, Stephanie Arnold, Jennifer Stern, Neil Frazer
JournalGynecologic oncology (Gynecol Oncol) Vol. 107 Issue 3 Pg. 554-62 (Dec 2007) ISSN: 1095-6859 [Electronic] United States
PMID17905420 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • BIRC5 protein, human
  • Biomarkers, Tumor
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Ointments
  • Survivin
  • terameprocol
  • Masoprocol
  • CDC2-CDC28 Kinases
Topics
  • Adolescent
  • Adult
  • Biomarkers, Tumor (biosynthesis)
  • CDC2-CDC28 Kinases (biosynthesis)
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Immunohistochemistry
  • Inhibitor of Apoptosis Proteins
  • Masoprocol (administration & dosage, adverse effects, analogs & derivatives, pharmacokinetics)
  • Microtubule-Associated Proteins (biosynthesis)
  • Neoplasm Proteins (biosynthesis)
  • Neoplasm Staging
  • Ointments
  • Papillomaviridae (classification)
  • Papillomavirus Infections (complications, virology)
  • Survivin
  • Uterine Cervical Neoplasms (drug therapy, metabolism, pathology, virology)
  • Uterine Cervical Dysplasia (drug therapy, metabolism, pathology, virology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: